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The 70.8 kDa protein, Dp71, is the major Duchenne muscular dystrophy (DMD) gene product m many nonmuscle tissues including the brain. 
Dp71 shares most of the C-terminal and cysteme-rich domains with the dystrophins but lacks the entire large rod shaped domain of spectrin-like 
repeats, and the N-terminal actin-binding domain. The function of Dp71 is unknown. Using subcellular fractionation and immunostaining we show 
that Dp71 IS associated with the plasma membrane. Dp71 IS also associated with the plasma membrane in md.u myogenic cells transfected with 
a vector expressing Dp71. 
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1. INTRODUCTION 
The main product of the DMD gene in the muscle is 
a 427 kDa protein called dystrophin. It consists of four 
domains: an N-terminal actin binding domain; spectrin- 
like repeats; a cysteine-rich region, sharing homology 
with the Ca*+ binding domain of Dictyostelium a-ac- 
tinin; and a C-terminal domain with no similarity to any 
other known protein [l], except for the dystrophin re- 
lated protein (DRP) [2]. Electron microscopy and cy- 
toimmunostaining studies have demonstrated that in 
the muscle, dystrophin is associated with the cell mem- 
brane [3,4]. This association is mediated by a number 
of glycoproteins which complex with dystrophin [5,6]. 
A very similar isoform of dystrophin is expressed in 
the brain. Its mRNA is transcribed from the same gene 
but it is regulated by a different promoter located 75- 
300 kb 5’ to the promoter of the muscle type dystrophin 
[7-141. 
Recently, we and others have described an additional 
product of the same gene having a mass of only 70.8 
kDa (Dp71) [15-191. This protein is expressed in many 
nonmuscle cell types and it is the major product of the 
DMD gene in brain, and in neuron and glia cell cultures 
[ 15-171. It is relatively abundant in embryonic stem cells 
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where it is the only detectable DMD gene product [20]. 
Dp71 does not contain the actin binding domain or the 
large region of spectrin-like repeats which confer a rod 
shape to dystrophin [15,16]. It does contain the cysteine- 
rich and the C-terminal domains of dystrophin. How- 
ever, due to alternative splicing, 13 amino acids are 
deleted in the C-terminal domain and the last 13 amino 
acids are replaced by 31 amino acids, which are not 
found in skeletal muscle dystrophin. This substitution 
increases the calculated hydrophobicity of the C-termi- 
nus of Dp71. In addition, the sequence encoding the 
first 7 amino acids at the N-terminus of the protein, and 
the 5’ untranslated region are located in a unique exon 
not present in dystrophin mRNA. This exon and the 
promoter of Dp71 are located in the intron between 
exon 62 and 63 of dystrophin mRNA ([17,18] and Le- 
derfein et al., in preparation). 
The occurrence of Dp71 in a wide range of cells and 
its regulated expression during early embryogenesis 
suggest that it has an important biological function, 
which is as yet unknown. To approach this question we 
investigated the cellular localization of Dp71. The re- 
sults presented here show that at least a significant frac- 
tion of Dp71 is associated with the cell membrane. 
These results also indicate that the cysteine-rich and the 
C-terminal domains are sufficient for the association 
with the plasma membrane. 
2. EXPERIMENTAL 
2.1. Cell cultures 
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2 2. Establishment of a mnyogenic cell he from mdx mice and transfec- 
tzon 
The MDXL myogemc cell hne was estabhshed from thigh muscle 
of 3-week-old mdx male mouse (Yaffe and Saxel. unpublished) using 
the culture condttions, and differenttal platmg, sertal cell passaging 
and cloning methods as descrtbed prevtously [21.22] The cells were 
grown and induced to differentiate as described m Yaffe and Saxel 
[22] The cells prohferated and differentiated m a manner similar to 
other myogemc cell lines, but dtd not express dystrophin. Cultures of 
proliferating mononucleated MDXL cells were cotransfected with a 
plasmtd containing the entire coding regton of the Dp71 cDNA under 
the control of the skeletal muscle actin gene promoter. and the plasmtd 
pTM which confers G418 resistance. G418 resistant clones expressing 
Dp71 after dtfferenttatton were Isolated and used for tmmunofluores- 
cence staining. 
2.3. Preparation oj subcellular fracttons 
Monolayer cultures of HepG2 cells were rinsed with PBS and the 
cells were collected usmg a rubber policeman and centrifuged for 10 
mm at 1,500 rpm The pellet was resuspended m a hypotonic solutton 
(10 mM HEPES, pH 74, 10 mM KC], 0.1 mM EDTA. 0 1 mM 
EGTA, 1 mM DTT. 0 5 mM PMSF. 1 @ml leupeptme, 1 pg/ml 
pepstatine. I pglml aprotenine) and homogemzed wtth a B-pestle 
Dounce homogenetzer (20 strokes). Nuclei were pelleted by IO mm of 
centrifugatton at 1.000 rpm. The supernatant fraction was centrifuged 
at 25.000 x g for I5 mm. The resulting supernatant contained mamly 
soluble protems and enzymes The pellet was resuspended m a buffer 
containing 0.3 M sucrose, 10 mM trtcme. pH 8. 1 mM K-EDTA, I 
mM PMSF, 0.1 mM PABA. 1 &ml leupeptm. 1 pg/ml pepstatm and 
layered on the top of a centrifuge tube containing several layers of 
sucrose m the above-menttoned buffer (20% and 35% sucrose). After 
spmnmg for 90 min at 25,000 rpm (Beckman rotor SW41). two frac- 
tions were collected. These were the Interphase between the 20% and 
35% sucrose layers, that contamed the plasma membrane (PM): and 
the pellet. that mostly contained mitochondrta and endoplasmic rettc- 
ulum (ER). The fracttonatton was done at 4°C. All the fractions were 
assayed for protein concentration (Bradford assay) and stored at 
-70°C. For Western blot analysis. the sample buffer components were 
added to a final concentratton of: 67.5 mM Tris-HCI (pH 6.8). 20% 
glycerol, 15% SDS, 5% 2-mercaptoethanol, 0 001% Bromophenol 
blue. 
The preparatton of subfractions from rat hver was done accordmg 
to Hirschberg et al. [23]. 
2 4. Western blot analvsw 
Western blot analysis was done usmg 3-10% polyacrylamide/SDS 
gradient gels as described by Laemmh [24] and modttied by Pons et 
al. [35]. Detection of the immunoreactive bands was done with the 
ECL kit (Amersham). 
2.5. Intnlunofluoresce~~ce stammg 
For indirect tmmunofluorescence stainmg. the cells were rinsed 
briefly with PBS and then fixed for 5 mm in cold methanol (-20°C). 
Fixed cells were then permeabilized wtth PBS, 0.2% Trtton X-100 for 
15 mm and blocked with PBS, 5% milk, 0.2% Triton X-100 for another 
30 mm. Incubattons of the antibodies (Abs) were done m PBS, 0.2% 
Triton X-100,5% milk at room temperature. The primary and second- 
ary Abs were incubated for 3 and I h. respecttvely, followed by several 
washes wtth PBS. Mounting was done m 60% glycerol. 2% n-propyl 
gallate and 0.2 M Trts-HCI (pH 8.1) 
2.6. .4ntibodles 
MANDRAI and MANDRA6 are monoclonal anttbodies (mAb) 
against two different epttopes m the C-termmal domain of human 
dystrophin. The two Abs do not react with DRP [36] NC1 Dys-1 1s 
a mAb agamst the mid rod domain with epnopes of human dystrophm 
(Novocastra Laboratones) R-156 IS a polyclonal antibody (pAb) 
raised against N-cadherin [27]. For tmmunofluorescence the second- 
ary Ab used was Rhodamme an&mouse TRITC from Jackson Im- 
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Fig 1. Distribution of Dp7l m subcellular fracttons of HepG2 cells. 
Protein samples (15 pg) were sized-fractionated on a 3-10% poly- 
acrylamtde/SDS gel. blotted onto a nitrocellulose sheet, and rm- 
munostained with the mAb MANDRAI (A) and pAb R-156(B) The 
positions of dystrophin (Dys). Dp71 and N-cadherm (N-CAD) are 
mdtcated. The samples are: total extract of HepG2: nuclei: mitochon- 
dria and endoplasmtc retrculum (MIT./ER); 25.000 x R supernatant 
(sup); plasma membrane (PM) and total skeletal muscle extract 
(sk. muscle) 
muno Laboratories Photographs were taken with a Axioskop Zeiss 
tmmunofluorescence mtcroscopy using Kodak T-max ASA 3200 film 
3. RESULTS 
3.1. Subcellular fractionation 
To determine the cellular localization of Dp71 we 
prepared subcellular fractions from human hepatoma 
HepG2 cells. The relative concentration of Dp71 in the 
various fractions was determined by Western blot anal- 
ysis using the mAb MANDRAl, which recognizes both 
dystrophin and Dp71 [16,26]. Dp71 is highly enriched 
in the sucrose-layer purified PM fraction. However, it 
is also present in other fractions (Fig. 1A). Recovery 
calculations indicated that 5-20% of total Dp71 was 
found in the purified PM fraction. As can be seen in Fig. 
1 B, the subcellular distribution of N-cadherin, a known 
membrane protein which is associated with cell-cell ad- 
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Fig. 2. Distrtbution of Dp71 in subcellular fractions of liver cells. 
Protein samples (4 pg) were sized-fractionated on a 3-10% poly- 
acrylamtde/SDS gel, blotted onto a nitrocellulose sheet, and im- 
munostained with the mAb MANDRAl (A) and pAb R-156 (B). The 
positions of dystrophin (Dys), Dp71 and N-cadherin (N-CAD) arc 
indicated. The samples are ER, heavy Golgi subfraction (Golgi). PM 
and total skeletal muscle and liver extracts. The lower band in the PM 
fraction may be a degradation product of Dp71. 
hesion [27], is similar to that of Dp71. It is therefore 
likely that all the fractions are contaminated to some 
extent with PM. 
In another experiment we compared the level of Dp71 
in PM, ER fractions and a heavy Golgi fraction ob- 
tained from normal rat liver [23]. The purity of each 
fraction and cross-contamination was tested by assay- 
ing the activity of enzyme markers for PM (alkaline 
phosphodiesterase), ER (glucose-6-phosphatase) or 
Golgi (galactosyltransferase). The PM was essentially 
free of ER (1.7% contamination). However, the ER 
fraction was contaminated with significant amounts of 
PM (33%) and the heavy Golgi subfraction was contam- 
inated with 13% of PM. As can be seen in Fig. 2A, Dp71 
is enriched in the highly purified PM fraction but is also 
present in the other fractions which are contaminated 
with PM. The distribution of Dp71 in liver fractions is 
similar to that of N-cadherin (Fig. 2B) as observed in 
the HepG2 subcellular fractions. 
These experiments show that Dp71 is associated with 
the PM. We cannot exclude the possibility that some 
Dp71 is also normally present in other cellular compart- 
ments. However, the similarity of the distribution of 
Dp71 and N-cadherin suggests that the presence of 
Dp7 1 in other fractions is mostly due to contamination 
with PM. 
3.2. Immunojhorescence localization of Dp71 in cells 
To further examine the localization of Dp71, we used 
the mAb MANDRAl for indirect immunofluorescence 
staining of cell types which do not express dystrophin. 
Fixed and permeabilized HepG2 and HeLa cells were 
first stained with MANDRAl followed by staining with 
rhodamine conjugated rabbit anti-mouse antibody. As 
can be seen in Fig. 3A, the immunofluorescence staining 
was associated with the cell membrane. No staining was 
observed with mAb NCL Dys-1 which recognizes an 
epitope in the spectrin-like repeat domain of dystro- 
phin, which is absent in Dp71 (Fig. 3C). No membrane 
associated staining was observed when mAb MAN- 
DRAl was omitted from the staining reaction (second 
Ab only; not shown). 
Membrane staining of HepG2 cells was also obtained 
with the mAb MANDRA6, which is directed against a 
different epitope in the C-terminal region of the protein 
(not shown). 
It should be pointed out that in the HepG2 cells the 
membrane staining was observed in regions of cell ag- 
gregates density with extensive cell-to-cell contact. We 
do not know whether this pattern of staining represents 
clonal diversity or a density-dependent stimulation of 
Dp71 expression. Further investigations are required in 
order to evaluate these possibilities. 
As can be seen in Fig. 4, the immunostaining of HeLa 
cells, with the mAb MANDRAl is also associated with 
the PM. 
Due to the low abundancy of Dp71 in liver tissues, 
we could not detect significant specific staining of Dp71 
in frozen liver sections. 
3.3. Localization of exogenous Dp71 expressed in mdx 
myogenic cells 
As described elsewhere, Dp71 is not detectable in 
differentiated muscle fibers [16,17]. It was of interest to 
test whether Dp71 expressed from a transfected gene is 
capable of binding to the muscle fiber sarcolemma. 
Due to a mutation resulting in a stop codon (nucleo- 
tide 3185 of dystrophin mRNA), md.x mice do not ex- 
press dystrophin [28]. The mutation does not affect the 
expression of Dp71 which is transcribed from the 3’ 
region of the gene in the relevant tissues. However, as 
in normal mice, Dp71 is undetectable in skeletal muscle 
of mdx mice ([16] and Fig. 5). 
A myogenic cell line established in our laboratory 
from md.s mice, MDXL, was transfected with a plasmid 
containing a cloned Dp71 cDNA under the control of 
the rat skeletal muscle actin gene promoter. Some of the 
transfected clones expressed Dp71 in differentiated cul- 
tures at a level comparable to the levels of dystrophin 
in muscle cell lines from normal mice. 
Specific staining of the muscle fiber membrane was 
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Fig. 3. Immunofluorescence staining of Dp71 in HepG2 cells. (A) Immunofluorescence staining with mAb MANDRAI. (B) Phase-contrast of the 
field shown in (A). (C) Immunofluorescence staining wzth mAb NCL Dys-1. Magnification: 350 x. 
observed only in differentiated MDXL myogenic cul- 
tures that expressed exogenous Dp7 1, indicating that at 
least a significant fraction of Dp71 expressed from the 
cloned cDNA became associated with the sarcolemma 
(Fig. 5). Since the only difference between the trans- 
fected and nontransfected cells is the expression of 
Dp71, this experiment also provides evidence that the 
membrane staining is not due to crossreaction of the 
mAb with other proteins. The intensity and distribution 
of the membrane staining was similar to that observed 
in L185 cells, a rat myogenic cell line that expresses 
dystrophin (not shown). 
4. DISCUSSION 
Both the immunostaining and the subcellular frac- 
tionation of HepG2 cells clearly demonstrate that in 
these cells Dp71 is primarily associated with the PM; 
however, the presence of some Dp71 in other cellular 
compartments cannot be excluded. Dp71 is also en- 
riched in a purified PM fraction in a normal liver tissue, 
and its presence in other subcellular fractions is proba- 
bly mainly due to contamination of these fractions with 
PM. 
Membrane staining with a mAb against an epitope in 
the C-terminal domain shared by dystrophin and Dp71 
was also observed in HeLa cells. These cells contain 
Dp71 mRNA and small amounts of dystrophin mRNA. 
However, only the Dp71 protein is detectable in extracts 
from these cells when analysed by Western blot (not 
shown). The specific membrane staining which is visible 
only with anti-C-terminal Abs indicates that Dp71 is 
also associated with the PM in HeLa cells. 
The interaction of dystrophin with the sarcolemma is 
mediated through binding to several ~lycoproteins 
[29,30]. It was first suggested [5] and then demonstrated 
[6] that the C-terminal and cysteine-rich domains of 
dystrophin are involved in this association. On the other 
hand, evidence coming from studies of DMD patients 
with truncated dystrophins that do not contain the C- 
terminal domain of the protein, suggested that the N- 
terminal domain and/or the spectrin-like repeats may be 
sufficient for the association of the protein with the 
membrane [31-331. 
As Dp71 contains only the C-terminal and cysteine- 
rich domains of dystrophin, our results indicate that 
these two domains of the protein are sufficient for mem- 
brane association in muscle and nonmuscle cells. It re- 
Fig. 4 immuno~uorescence staining of Dp71 in HeLa cells. ImmunoNuorescence staining with mAb MANDRAI (A) and mAb NCL Dys-I (B). 
Magnlfi~ation. 350 x. 
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Fig. 5. Immunofluorescence staining of exogenous Dp71 in mdx myogenic cells: (A) Differentiated, stable transfected MDXL cultures expressing 
exogenous Dp71. (B) Control untransfected differentiated MDXL cultures. Stained with mAb MANDRAI. Magnificatton. 400 x. 
mains to be determined whether Dp71 binds to the same 
glycoproteins that bind dystrophin, other glycopro- 
teins, or whether it is associated with the cell membrane 
by a different mechanism. 
On the basis of the rod-shaped structure of dystro- 
phin, its localization to the membrane, and the damage 
of the sarcolemma in DMD patients, it was speculated 
that dystrophin is a cytoskeletal protein which provides 
mechanical support to the membrane in skeletal muscle. 
Other studies have shown some linkage between dystro- 
phin and the calcium leak channels (reviewed in [34]). 
Dp71 is a much smaller, nonfibrilar, membrane-associ- 
ated protein, containing potential Ca’+ binding sites, 
and is expressed in many nonmuscle cell types. As Dp7 1 
does not contain the spectrin-like repeats and the actin 
binding domain of dystrophin it is unlikely that this 
protein functions as a mechanical support to the cell 
membrane. In view of its localization, relative abun- 
dancy in embryonic stem cells and early embryos, the 
possibility that Dp71 is involved in interactions between 
cells should be investigated. 
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